Select a medication above to begin.
Romvimza
vimseltinib
Adult Dosing .
Dosage forms: CAP: 14 mg, 20 mg, 30 mg
Special Note
- [uses, dosing may vary]
- Info: refer to institution protocols and pkg insert prior to prescribing for uses and dosing incl. toxicity-related dose adjustments
tenosynovial giant cell tumor, symptomatic
- [30 mg PO 2x/wk]
- Info: for pts in whom surgical resection may worsen functional limitation or cause severe morbidity; ensure >72h between doses; do not open/crush/chew cap
renal dosing
- [see below]
- eGFR >30: no adjustment; eGFR <30: not defined
- HD/PD: not defined
hepatic dosing
- [see below]
- bilirubin 1.1-1.5x ULN or AST >ULN: no adjustment; bilirubin >1.5x ULN: not defined
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.
Contraindications / Cautions .
- hypersensitivity to drug or ingredient
- liver transaminases elevated
- bilirubin >ULN
- hepatic dz, active
- biliary tract dz, active
- avoid: breastfeeding during tx and x1mo after D/C
- caution: hypersensitivity to tartrazine
- caution: pts of childbearing potential
- caution: male pts of reproductive potential
Drug Interactions .
Overview
vimseltinib
kinase inhibitor
- BCRP inhibitor
- OCT2 inhibitor
- P-gp inhibitor, strong
- content coming soon
Contraindicated
- colchicine
Avoid/Use Alternative
- alpelisib
- apixaban
- cladribine oral
- dabigatran
- dofetilide
- doxorubicin
- ensartinib
- futibatinib
- lefamulin
- lenacapavir
- neratinib
- pazopanib
- pralsetinib
- repotrectinib
- rivaroxaban
- silodosin
- sirolimus
- sirolimus albumin-bound
- topotecan
- venetoclax
Monitor/Modify Tx
- afatinib
- aliskiren
- atorvastatin
- avatrombopag
- carvedilol
- ceritinib
- crizotinib
- cyclosporine
- darolutamide
- daunorubicin
- deflazacort
- digoxin
- diltiazem
- edoxaban
- enfortumab vedotin
- etoposide
- everolimus
- fluvastatin
- gilteritinib
- glecaprevir
- idelalisib
- imatinib
- irinotecan
- ivosidenib
- ixabepilone
- lapatinib
- larotrectinib
- loperamide
- lovastatin
- maraviroc
- mavorixafor
- metformin
- methotrexate
- mitoxantrone
- morphine
- naldemedine
- nintedanib
- paclitaxel
- pibrentasvir
- pindolol
- pitavastatin
- posaconazole
- pravastatin
- procainamide
- quinidine (antiarrhythmic)
- quinidine (CYP2D6 inhibitor)
- quinine
- ranolazine
- red yeast rice
- relugolix
- rifampin
- rifaximin
- rimegepant
- riociguat
- romidepsin
- rosuvastatin
- simvastatin
- tacrolimus
- talazoparib
- tenofovir alafenamide
- tenofovir disoproxil
- ticagrelor
- tipranavir
- tolvaptan
- ubrogepant
- vinblastine
- vincristine
- vinorelbine
Caution Advised
- dalfampridine
- lamivudine
- memantine
- pramipexole
- seladelpar
- sulfasalazine
Adverse Reactions .
Serious Reactions
- hepatotoxicity
Common Reactions
- edema
- fatigue
- rash
- pruritus
- HTN
- lacrimation incr.
- neuropathy
- dry eyes
- visual impairment
- ALT or AST incr.
- cholesterol incr.
- neutrophils decr.
- leukocytes decr.
Safety/Monitoring .
Monitoring Parameters
pregnancy test at baseline; LFTs, incl. ALT, AST, total bilirubin, direct bilirubin, alk phos, GGT, at baseline, then 2x/mo x2mo, then q3mo during 1st year of tx, then as clinically indicated
Pregnancy/Lactation .
Pregnancy
Clinical Summary
weigh risk/benefit during pregnancy; no human data available; risk of teratogenicity based on animal data at 3x systemic exposure and drug's mechanism of action
Individuals of Reproductive Potential
obtain pregnancy test before tx start; avoid pregnancy by using effective contraception during tx and x1mo after D/C in pts of childbearing potential and male pts
Lactation
Clinical Summary
avoid breastfeeding during tx and x1mo after D/C; no human data available to assess risk of infant harm or effects on milk production
Pharmacology .
Metabolism: oxidation; CYP450: none
Excretion: feces 43% (9.1% unchanged), urine 38% (5.1% unchanged); Half-life: 6 days
Subclass: Kinase Inhibitors, CSF1R Inhibitors
Mechanism of Action
inhibits colony stimulating factor 1 receptor (CSF1R), CSF1R autophosphorylation, and CSF1R-mediated downstream signaling, leading to inhibition of CSF1R-dependent tumor cell proliferation
Formulary .
No Formulary Selected
Join Now to View Patient Handouts!
Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.
Current Members: Sign In.
Pill Pictures
Join Now to View Pill Pictures!
Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.
Current Members: Sign In.